Yamamoto F, Igimi H
Yamamoto Surgical Hospital.
Nihon Rinsho. 1993 Jul;51(7):1791-6.
We have developed GS-100, a new direct dissolving drug with strong dissolution property for cholesterol stone by supplementing d-limonene, a dissolvent used since 1974, with 30% medium-chain monoglyceride (MCM). The new drug was applied in 23 patients with gallbladder stones and three with bile duct stone. The presumptive analysis of the composition of the stones was drawn from the CT recordings. As non-invasive therapies, methyl tert-butyl ether (MTBE) dissolution and extracorporeal shock wave lithotripsy (ESWL), which are commonly used in Europe and America, have been reported as being favourable; however, GS-100 is superior in respect to safety and applicative dimension, suggesting of the possibility of using GS-100 as an important drug in the non-invasive therapy for gallstone in the near future.
我们研发了GS - 100,这是一种新型直接溶解药物,通过在自1974年起就已使用的溶剂d - 苎烯中添加30%的中链甘油单酯(MCM),对胆固醇结石具有很强的溶解性能。该新药应用于23例胆囊结石患者和3例胆管结石患者。结石成分的推测分析来自CT记录。作为非侵入性治疗方法,欧美常用的甲基叔丁基醚(MTBE)溶解法和体外冲击波碎石术(ESWL)已被报道效果良好;然而,GS - 100在安全性和应用范围方面更具优势,这表明在不久的将来,GS - 100有可能成为胆结石非侵入性治疗中的一种重要药物。